المؤلفون: Santoni M., Heng D. Y., Bracarda S., Procopio G., Milella M., Porta C., Matrana M. R., Carteni G., Crabb S. J., De Giorgi U., Basso U., Masini C., Calabro F., Vitale M. G., Santini D., Massari F., Galli L., Fornarini G., Ricotta R., Buti S., Zucali P., Caffo O., Morelli F., Carrozza F., Martignetti A., Gelibter A., Iacovelli R., Mosca A., Atzori F., Vau N., Incorvaia L., Ortega C., Scarpelli M., Lopez-Beltran A., Cheng L., Paolucci V., Graham J., Pierce E., Scagliarini S., Sepe P., Verzoni E., Merler S., Rizzo M., Sorgentoni G., Conti A., Piva F., Cimadamore A., Montironi R., Battelli N.

المساهمون: Santoni, M., Heng, D. Y., Bracarda, S., Procopio, G., Milella, M., Porta, C., Matrana, M. R., Carteni, G., Crabb, S. J., De Giorgi, U., Basso, U., Masini, C., Calabro, F., Vitale, M. G., Santini, D., Massari, F., Galli, L., Fornarini, G., Ricotta, R., Buti, S., Zucali, P., Caffo, O., Morelli, F., Carrozza, F., Martignetti, A., Gelibter, A., Iacovelli, R., Mosca, A., Atzori, F., Vau, N., Incorvaia, L., Ortega, C., Scarpelli, M., Lopez-Beltran, A., Cheng, L., Paolucci, V., Graham, J., Pierce, E., Scagliarini, S., Sepe, P., Verzoni, E., Merler, S., Rizzo, M., Sorgentoni, G., Conti, A., Piva, F., Cimadamore, A., Montironi, R., Battelli, N.

مصطلحات موضوعية: Cabozantinib, Nivolumab, Prognosi, Real-world data, Renal cell carcinoma, Targeted therapy

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31905816; info:eu-repo/semantics/altIdentifier/wos/WOS:000516826700084; volume:12; issue:1; numberofpages:13; journal:CANCERS; https://hdl.handle.net/11566/277638Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85077345577

الإتاحة: https://doi.org/10.3390/cancers12010084Test
https://hdl.handle.net/11566/277638Test

المؤلفون: Santoni M., Massari F., Bracarda S., Procopio G., Milella M., De Giorgi U., Basso U., Aurilio G., Incorvaia L., Martignetti A., Rizzo M., Carteni G., Grande E., Matrana M. R., Crabb S. J., Vau N., Sorgentoni G., Cimadamore A., Montironi R., Battelli N.

المساهمون: Santoni M., Massari F., Bracarda S., Procopio G., Milella M., De Giorgi U., Basso U., Aurilio G., Incorvaia L., Martignetti A., Rizzo M., Carteni G., Grande E., Matrana M.R., Crabb S.J., Vau N., Sorgentoni G., Cimadamore A., Montironi R., Battelli N.

مصطلحات موضوعية: Body mass index, Cabozantinib, Obesity, Prognosis, Real-world data, Renal cell carcinoma, Targeted therapy

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33477676; info:eu-repo/semantics/altIdentifier/wos/WOS:000611046400001; volume:11; issue:1; numberofpages:10; journal:DIAGNOSTICS; http://hdl.handle.net/10447/555876Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107976588

الإتاحة: https://doi.org/10.3390/diagnostics11010138Test
http://hdl.handle.net/10447/555876Test

المؤلفون: Jones, R. J., Hussain, S. A., Birtle, A. J., Song, Yee Pei, Enting, D., Faust, G., Hilman, S., Jagdev, S., McGovern, U. B., Parikh, O., Lewis, A., Soulis, E., Trevethan, A., Crabb, S. J., Powles, T.

المساهمون: University of Glasgow, Glasgow

العلاقة: https://dx.doi.org/10.1200/JCO.2022.40.17_suppl.LBA4505Test; Jones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, et al. A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison. Journal of Clinical Oncology. 2022 Jun;40(17). PubMed PMID: WOS:000891791500024.; http://hdl.handle.net/10541/626048Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA4505Test
http://hdl.handle.net/10541/626048Test

المؤلفون: Crabb, S. J., Dempsey, L., Soulis, E., Hinsley, S., Song, Yee Pei, Barber, J., Frew, J., Gale, J., Faust, G., Brock, S., McGovern, U. B., Parikh, O. A., Enting, D., Sundar, S., Ratnayake, G., Lees, K., Hussain, S. A., Powles, T. B., Jones, R., Tapper, W.

المساهمون: Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton

العلاقة: https://dx.doi.org/10.1016Test/j.annonc.2022.07.1850; Crabb SJ, Dempsey L, Soulis E, Hinsley S, Song YP, Barber J, et al. Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform. Annals of Oncology. 2022 Sep;33(7):S1348-S. PubMed PMID: WOS:000866211602322.; http://hdl.handle.net/10541/625982Test; Annals of Oncology

الإتاحة: https://doi.org/10.1016Test/j.annonc.2022.07.1850
http://hdl.handle.net/10541/625982Test

المؤلفون: Crabb, S. J., Hussain, S. A., Soulis, E., Hinsley, S., Dempsey, L., Trevethan, A., Song, Yee Pei, Barber, J., Frew, J. A., Gale, J., Faust, G., Brock, S. J., McGovern, U. B., Parikh, O., Enting, D., Sundar, S., Ratnayake, G., Lees, K., Powles, T., Jones, R. J.

المساهمون: Southampton Experimental Cancer Medicine Centre, Southampton

العلاقة: https://dx.doi.org/10.1200/JCO.2022.40.6_suppl.436Test; Crabb SJ, Hussain SA, Soulis E, Hinsley S, Dempsey L, Trevethan A, et al. A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm. Vol. 40, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 436–436.; http://hdl.handle.net/10541/625227Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2022.40.6_suppl.436Test
http://hdl.handle.net/10541/625227Test

المؤلفون: Crabb, S. J., Hussain, S., Soulis, E., Hinsley, S., Dempsey, L., Trevethan, A., Song, Yee Pei, Barber, J., Frew, J., Gale, J., Faust, G., Brock, S., McGovern, U., Parikh, O., Enting, D., Sundar, S., Ratnayake, G., Lees, K., Birtle, A. J., Powles, T., Jones, R. J.

المساهمون: Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, United Kingdom

العلاقة: https://dx.doi.org/10.1200/jco.22.00405Test; Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, et al. A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Aug 12:JCO2200405. PubMed PMID: 35960902. Epub 2022/08/13. eng.; http://hdl.handle.net/10541/625565Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/jco.22.00405Test
http://hdl.handle.net/10541/625565Test

المؤلفون: Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Qureshi, M., Elliott, Tony, Crabb, S. J., Huddart, R. A., Vasudev, N., Birtle, A. J., Worlding, J., James, N. D., Parikh, O., Vilarino-Varela, M., Alonzi, R., Linch, M. D., Riaz, I. B., Catto, J. W. F., Powles, T., Jones, R. J.

المساهمون: Department of Oncology and Metabolism, Academic Unit of Oncology, University of Sheffield, Sheffield, UK.

العلاقة: https://dx.doi.org/10.1016/s1470-2045Test(22)00158-9; Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Vol. 23, The Lancet Oncology. Elsevier BV; 2022. p. 650–8.; http://hdl.handle.net/10541/625261Test; Lancet Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(22)00158-9
http://hdl.handle.net/10541/625261Test

المؤلفون: Wong R. L., Ferris L. A., Do O. A., Holt S. K., Ramos J. D., Crabb S. J., Sternberg C. N., Bellmunt J., Ladoire S., De Giorgi U., Harshman L. C., Vaishampayan U. N., Necchi A., Srinivas S., Pal S. K., Niegisch G., Dorff T. B., Galsky M. D., Yu E. Y.

المساهمون: Wong, R. L., Ferris, L. A., Do, O. A., Holt, S. K., Ramos, J. D., Crabb, S. J., Sternberg, C. N., Bellmunt, J., Ladoire, S., De Giorgi, U., Harshman, L. C., Vaishampayan, U. N., Necchi, A., Srinivas, S., Pal, S. K., Niegisch, G., Dorff, T. B., Galsky, M. D., Yu, E. Y.

مصطلحات موضوعية: Antineoplastic agents, carboplatin, Cisplatin, combination, Drug therapy, Platinum compounds, Urinary bladder neoplasms, Urologic neoplasms

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000685434900001; journal:THE ONCOLOGIST; http://hdl.handle.net/20.500.11768/118315Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85112815550

الإتاحة: https://doi.org/20.500.11768/118315Test
https://doi.org/10.1002/onco.13925Test
https://hdl.handle.net/20.500.11768/118315Test

المؤلفون: Jones, R. J., Bahl, A., De Bono, J. S., Ralph, C., Elliott, Tony, Robinson, A., Westbury, C., Birtle, A. J., Staffurth, J. N., Protheroe, A., Venugopal, B., Thomson, F., Pou, C., Morris, Karen, Tugwood, Jonathan D, Divers, L., Hopkins, C., McCartney, E., Kelly, C., Crabb, S. J.

المساهمون: Institute of Cancer Sciences, Glasgow

العلاقة: https://dx.doi.org/10.1200/JCO.2021.39.6_suppl.107Test; Jones RJ, Bahl A, De Bono JS, Ralph C, Elliott T, Robinson A, et al. SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group. JCO. 2021 Feb 20;39(6_suppl):107–107.; http://hdl.handle.net/10541/623972Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2021.39.6_suppl.107Test
http://hdl.handle.net/10541/623972Test

المؤلفون: Martinez Chanza N., Werner L., Plimack E., Yu E. Y., Alva A. S., Crabb S. J., Powles T., Rosenberg J. E., Baniel J., Vaishampayan U. N., Berthold D. R., Ladoire S., Hussain S. A., Milowsky M. I., Agarwal N., Necchi A., Pal S. K., Sternberg C. N., Bellmunt J., Galsky M. D., Harshman L. C.

المساهمون: Martinez Chanza, N., Werner, L., Plimack, E., Yu, E. Y., Alva, A. S., Crabb, S. J., Powles, T., Rosenberg, J. E., Baniel, J., Vaishampayan, U. N., Berthold, D. R., Ladoire, S., Hussain, S. A., Milowsky, M. I., Agarwal, N., Necchi, A., Pal, S. K., Sternberg, C. N., Bellmunt, J., Galsky, M. D., Harshman, L. C.

مصطلحات موضوعية: Adjuvant chemotherapy, Muscle-invasive bladder cancer, Muscle-invasive urinary tract cancer, Neoadjuvant chemotherapy, Residual disease, Risk of relapse, Time to recurrence

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000579524700013; volume:3; issue:5; firstpage:671; lastpage:679; numberofpages:9; journal:EUROPEAN UROLOGY ONCOLOGY; http://hdl.handle.net/20.500.11768/118314Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85068568638

الإتاحة: https://doi.org/20.500.11768/118314Test
https://doi.org/10.1016Test/j.euo.2018.12.013
https://hdl.handle.net/20.500.11768/118314Test